BioPharmSignal logoBioPharmSignal

Biotech News

NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session

NewAmsterdam Pharma (NAMS)NewAmsterdam PharmaCompany update

NAARDEN, The Netherlands and MIAMI, March 23, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”)

Related news

NAMSNewAmsterdam Pharma2026-06-03 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions

NAMSNewAmsterdam Pharma2026-07-01 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

LXRXLexicon Pharmaceuticals2026-03-24 12:00 EST

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

MISTMilestone Pharmaceuticals Inc.2026-03-16 12:13 EST

Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

LXRXLexicon Pharmaceuticals2026-06-03 12:00 EST

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

SGMTSagimet Biosciences2026-04-06 11:00 EST

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BLTEBelite Bio2026-07-06 11:00 EST

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

RYTMRhythm Pharmaceuticals2026-05-28 12:00 EST

Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics

RYTMRhythm Pharmaceuticals2026-06-15 20:01 EST

Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026

ALTAltimmune2026-05-13 11:15 EST

Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026

View all latest news

NewAmsterdam Pharma

Oral Lipid-Lowering Therapies NewAmsterdam Pharma develops oral therapies for cardiovascular disease. Its lead program targets CETP to produce substantial reductions in LDL cholesterol. Obicetrapib Obicetrapib is an oral CETP inhibitor being developed for patients who need additional LDL reduction despite existing lipid-lowering...

Recent company news

NAMSNewAmsterdam Pharma2026-08-06 20:01 EST

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAMSNewAmsterdam Pharma2026-08-05 11:00 EST

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NAMSNewAmsterdam Pharma2026-07-29 12:00 EST

NewAmsterdam Pharma to Host Investor Day on August 5, 2026

NAMSNewAmsterdam Pharma2026-07-24 12:00 EST

NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)

NAMSNewAmsterdam Pharma2026-07-02 20:01 EST

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
27.67 USD
Market cap
3.71B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States